Isoniazid in Children – Any Rationale for Post Isoniazid Liver Function Test?

Ahmad Fadzil  Bin Abdullah; Nur Shafinaz Rusli

doi:10.51407/mjpch.v28i1.190

Authors

Ahmad Fadzil Bin Abdullah Department of Pediatrics, Sultan Ahmad Shah Medical Centre @ IIUM, 25 200 Kuantan, Pahang Darul Makmur, Malaysia
Nur Shafinaz Rusli Department of Pediatrics, Sultan Ahmad Shah Medical Centre @ IIUM, 25200 Kuantan, Pahang Darul Makmur, Malaysia

DOI:

https://doi.org/10.51407/mjpch.v28i1.190

Keywords:

Isoniazid, Anti-TB drug-induced liver injury (ATLI), latent Tuberculosis infection (LTBI)

Abstract

Isoniazid (INH) therapy remains the treatment of choice in latent tuberculosis infection (LTBI). However, drug-induced liver injury (DILI) is a known adverse effect of isoniazid. Serum transaminase elevation occurs in about 10% of children receiving INH monotherapy. Drug-induced liver injury can range from asymptomatic increase of aminotransferase to severe liver injury, or in some cases hepatic failure. Even though INH-induced liver injury has been known and extensively studied, its underlying mechanisms are still not fully understood. The liver injury comprises hepatotoxicity and a rarer form of hepatitis hypersensitive allergic reaction. Since the facility to do liver function (LFT) is widely available, monitoring liver function while on INH therapy is the wisest way of monitoring acute liver injury (ATLI).

Downloads

Download data is not yet available.

References

Bhandari R., Pharmacokinetics Kaur I.P. tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm. 2013; 441:202–212.

Singh N., Golani A., Patel Z., Maitra A. Transfer of isoniazid from circulation to breast milk in lactating women on chronic therapy for tuberculosis. Br J Clin Pharmacol. 2008; 65:418–422.

Vuilleumier N., Rossier M.F., Chiappe A., Degoumois F., Dayer P., Mermillod B. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol. 2006; 62:423–429.

Tafazoli S., Mashregi M., O׳Brien P.J. Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicol Appl Pharmacol. 2008; 229:94–101.

Mushiroda T., Yanai H., Yoshiyama T., Sasaki Y., Okumura M., Ogata H., et al. Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients. Hum Genome Var 2016; 3:16014.

Donald P.R. Antituberculosis drug-induced hepatotoxicity in children. Pediatric Reports 2011; volume 3: e16.

Boelsterli U.A., Lee K.K. Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress. J Gastroenterol Hepatol 2014; 29:678–87.

Grönhagen-Riska C, Hellstrom PE, Fröseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118:461.

Saukkonen JJ, Cohn DL, Jasmer RM. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935–52.

Chang SH, Nahid P, and Reitzman S. Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection. Isoniazid Hepatotoxicity in Children. J Pediatric Infect Dis Soc 2014; 9(3):221-7

Wu SS, Chao CS, Vargas JH, et al. Isoniazid-related hepatic failure in children: A survey of liver transplantation centers. Transplantation 2007; 84:173–9. 3.

Chang T.E., Huang Y.S.., Su WJ., Perng C.L., Huang Y.H., Hou M.C. The role of regular liver function monitoring in antituberculosis drug-induced liver injury. J Chin Med Assoc 2019; 82:7.

Chih LH, On AWF, Huang YS. Correlation of antituberculosis drug-related liver injury and liver function monitoring: a 12-year experience of the Taiwan drug relief foundation. J Food Drug Anal 2014; 22:356–62.

World Health Organisation (WHO). Latent Tuberculosis Infection Updated and consolidated guidelines for programmatic management 2018.